GlassScriptPhysician profile
Pooja D Paranjpe
NPI 1922218973
$1,823.64
in general payments reported to CMS, 2019-2025
17 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $97.81 · 2021: $154 · 2022: $259 · 2023: $106 · 2024: $257 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.43 | 2019-2025 | Tezspire, Airsupra |
| Genzyme Corporation | $165.18 | 2022-2023 | |
| Grifols USA, LLC | $155.81 | 2024 | Xembify |
| Regeneron Healthcare Solutions, INC. | $142.01 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $121.86 | 2025 | Ayvakit |
| Sight Sciences, INC. | $115.69 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaxosmithkline, LLC. | $67.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.86 | 2019-2020 | |
| Csl Behring | $51.79 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $49.03 | 2019 | |
| Shire North American Group INC | $45.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.53 | 2020-2021 | |
| Alk-Abello, INC | $29.13 | 2019 | |
| Octapharma USA, INC. | $27.60 | 2019 | |
| Genentech USA, INC. | $17.70 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.34 | 2019 | |
| Aimmune Therapeutics, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Paranjpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.